At the 2018 ASCO Annual Meeting, we had the opportunity to connect with many ACCC members and engage a wide audience! Oncology Business Review, OncLive, and ASCO Post sat down with a number of ACCC advocates and leaders to discuss pressing issues in cancer care.
ACCC Treasurer Randall A. Oyer, MD, with an update on the ACCC Immuno-Oncology Institute:
ACCC Immuno-Oncology Institute Executive Committee Member Ivo Abraham, PhD, RN, speaks about value in cancer care:
ACCC Past President Jennie R. Crews, MD, MMM, FACP, describes how care coordination in immunotherapy is engaging new providers with the cancer care team:
Dr. Abraham shares his perspective on hurdles to adoption of biosimilars in oncology:
Watch more from Dr. Abraham on:
Key features of a biosimilar - via OBR
Biosimilars approved and nearing approval for oncology - via OBR
Biosimilar pricing and reimbursement - via OBR
Dr. McBride Discusses financial toxicity in oncology with OncLive:
Lee S. Schwartzberg, MD, FACP, discusses how the ACCC Immuno-Oncology Institute is evolving to support integration of IO in the community through new working groups, resources for cross-specialty care coordination, and team education for this rapidly expanding field. - ASCO Post
Dr. Zibelman discusses managing immune-related adverse events with OncLive:
Posted 6/13/2018
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
